Hints and tips:
Related Topics
...The drug – MK-3682, uprifosbuvir – was obtained by Merck in its 2014 acquisition of Idenix Pharmaceuticals, which it snapped up in hopes of bolstering its position in the race to develop a new generation...
...Gilead had disputed that it had relied on Idenix’s intellectual property in making its blockbuster drugs, and said the patent was invalid....
...For Merck, the takeover of Cubist marks its second large deal in six months after its $3.85bn acquisition in June of Idenix Pharmaceuticals, a hepatitis C specialist....
...Similar factors were behind deals such as Roche’s $8.3bn takeover of InterMune and Merck’s acquisition of Cubist and Idenix in two further multibillion-dollar transactions last year....
...Centerview’s other high-profile pharmaceuticals deals in the last two years include Salix’s $14.5bn sale to Valeant; Intermune’s $8.3bn sale to Roche; Idenix’s $3.85bn sale to Merck & Co last year; and Onyx...
...Merck & Co has agreed to buy Idenix Pharmaceuticals for $3.85bn in a deal aimed at bolstering its position in the hotly contested race to develop a new generation of hepatitis C treatments....
...The whopping 240 per cent premium Merck is paying for hepatitis drug developer Idenix Pharmaceuticals got us wondering about the largest prices, in excess of market, paid in M&A deals....
...Idenix has fewer than 100 employees and no products on the market....
...Premium pricing: The whopping 240 per cent premium Merck is paying for hepatitis drug developer Idenix Pharmaceuticals got the FT’s Sujeet Indap wondering about the largest prices, in excess of market, paid...
...group is Gilead Sciences, whose hepatitis C medicine, Sovaldi, broke industry records in 2014 by generating about $10bn of sales in its first year. 2014 deals: Merck bought biotech companies cubist and Idenix...
...Merck just spent $3.85bn to buy Idenix, a nucleotide developer, making way for one pill containing all three types....
...Merck deal for Idenix sets record for highest premium Multibillion-dollar deals have been a regular occurrence in the pharmaceuticals industry recently, but Merck & Co’s $3.85bn acquisition of Idenix Pharmaceuticals...
...Dr Schinazi has founded or co-founded five virology companies including Triangle Pharmaceuticals, focusing on HIV and hepatitis B and bought by Gilead in 2003, and Idenix Pharmaceuticals, another hepatitis...
...AbbVie and Bristol-Myers Squibb are nearing market with similar drugs, and in June Merck & Co paid $3.85bn to buy Idenix, a hepatitis C specialist, to strengthen its position....
...(Financial Times) Merck & Co has agreed to buy Idenix Pharmaceuticals for $3.85bn in a deal aimed at bolstering its position in the hotly contested race to develop a new generation of hepatitis C treatments...
...Both Jeremy Clark, the original inventor of PSI-6130, and Idenix are now involved in patent litigation cases....
...It led to an immediate jump in the share prices of two other groups – Idenix and Achillion – that are independently developing hepatitis C treatments....
...Giants such as Johnson & Johnson, Abbott and Bristol-Myers Squibb, along with start-ups including Inhibitex, Achillion and Idenix, all have potential rivals to Incivek in the clinic....
...That drove up shares in other treatment developers as Idenix Pharmaceuticals surged 37 per cent to $9.66. Bristol-Myers Squibb was off 0.9 per cent to $33.91....
...Idenix Pharmaceuticals – originally named Novirio – was created by Jean-Pierre Sommadossi, a professor at Alabama, to help develop the drug, initially in co-operation with CNRS....
...Dr Benhamou is listed in public filings as a consultant to other drug companies including Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Idenix Pharmaceuticals; Roche; Valeant; and Vertex....
...This followed the $525m deal it made in March with US biotechnology firm Idenix Pharmaceuticals....
International Edition